ArrowMark Colorado Holdings LLC NAMS NEWAMSTERDAM PHARMA COMPANY

Ownership history in ArrowMark Colorado Holdings LLC  ·  10 quarters on record

AI Ownership Summary

ArrowMark Colorado Holdings LLC reported NEWAMSTERDAM PHARMA COMPANY (NAMS) in 10 quarterly 13F filings from 2024 Q1 through 2026 Q2. Peak portfolio weight reached 0.3% in 2026 Q2. The latest visible filing shows NAMS at 0.30% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this NAMS ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was ArrowMark Colorado Holdings LLC's position in NEWAMSTERDAM PHARMA COMPANY, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q2

NAMS was reported at 0.30% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.3% in 2026 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2026 Q2

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How ArrowMark Colorado Holdings LLC held NAMS — position size vs. price
% of Fund (quarterly)    NAMS price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q2 REDUCED 211,843 -47,681 -18.4% 0.30% $7.2M 2026-08-13 $26.67
2026 Q1 REDUCED 12.9% +5.8% 259,524 -38,553 -12.9% 0.22% $8.3M 2026-05-15 $35.44
2025 Q4 REDUCED 298,077 -12,922 -4.2% 0.23% $10.5M 2026-02-17 $35.24
2025 Q3 REDUCED 13.3% +23.1% 310,999 -47,615 -13.3% 0.16% $8.8M 2025-11-14 $38.35
2025 Q2 REDUCED 358,614 -3,108 -0.9% 0.12% $6.5M 2025-08-14 $25.17
2025 Q1 ADDED 361,722 +16,674 +4.8% 0.12% $7.4M 2025-05-15 $18.70
2024 Q4 REDUCED 345,048 -9,927 -2.8% 0.12% $8.9M 2025-02-14 $19.91
2024 Q3 ADDED 354,975 +57,806 +19.5% 0.08% $5.9M 2024-11-14 $24.97
2024 Q2 ADDED 297,169 +362 +0.1% 0.07% $5.7M 2024-08-14 $17.00
2024 Q1 INITIATED 296,807 0.08% $7.0M 2024-05-15 $19.81

FAQ About ArrowMark Colorado Holdings LLC and NAMS

These are the practical questions this page is built to answer before you even open the full history table.

How long has ArrowMark Colorado Holdings LLC reported owning NAMS?

ArrowMark Colorado Holdings LLC reported NAMS across 10 quarterly 13F filings, from 2024 Q1 through 2026 Q2.

What was the largest reported NAMS position in ArrowMark Colorado Holdings LLC's portfolio?

The largest reported portfolio weight for NAMS was 0.30% in 2026 Q2.

What is the latest reported NAMS position on this page?

The most recent filing on this page is 2026 Q2, when ArrowMark Colorado Holdings LLC reported 211,843 shares, equal to 0.30% of portfolio, with an estimated market value of $7.2M.

What does the chart on this NAMS ownership page compare?

The chart compares ArrowMark Colorado Holdings LLC's quarterly NAMS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did ArrowMark Colorado Holdings LLC time their NAMS position?

Based on 13F filing dates vs. subsequent NAMS price moves, ArrowMark Colorado Holdings LLC correctly timed 5 out of 9 reported position changes (56%). The annualised alpha on NAMS relative to SPY over the holding period was +309.6%.

← Back to ArrowMark Colorado Holdings LLC Holdings